Amneal Pharmaceuticals Announces Interim Results from ELEVATE-PD Study
Amneal Pharmaceuticals announced new interim results from its ongoing Phase 4 ELEVATE-PD study, which are being presented at the Advanced Therapeutics in Movement & Related Disorders, or ATRMD, 2026 Congress on June 5. The entire study population evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to Crexont extended-release capsules, regardless of whether patients switched from immediate-release carbidopa/levodopa, IR CD/LD plus a COMT inhibitor, or Rytary extended-release capsules. These interim findings build on the established efficacy and safety profile of Crexont demonstrated in the Phase 3 RISE-PD trial, and reflected in the FDA-approved prescribing information. After patients switched from prior therapies, treatment with Crexont delivered meaningful increases in "Good On" time, reductions in "Off" time, and improved motor symptom control. Patients switching from Rytary achieved consistent gains in continuous "Good On" intervals, the length of uninterrupted time patients experience "Good On." The most common adverse events in the study were dizziness, fall, nausea, dyskinesia, hallucination and headache.
